STOCK TITAN

Scynexis Inc - SCYX STOCK NEWS

Welcome to our dedicated news page for Scynexis (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scynexis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scynexis's position in the market.

Rhea-AI Summary
SCYNEXIS, Inc. (SCYX) reports positive financial results for 2023, with significant progress in developing SCY-247 and advancing clinical studies. The company ended 2023 with $98.0 million in cash and projects a cash runway of over two years. Phase I initiation for SCY-247 is expected in the second half of 2024, with promising preclinical results against fungal pathogens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that David Angulo, M.D., President and CEO, will present at Guggenheim’s 6th Annual Biotechnology Conference on February 7, 2024. The conference will include a fireside chat and one-on-one meetings, and will be held in New York, NY. The webcast link will be available for those who cannot attend in person.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
Rhea-AI Summary
SCYNEXIS, Inc. presents preclinical efficacy data on SCY-247, a second-generation fungerp candidate showing promising results in treating mucormycosis. The oral SCY-247 demonstrated a response rate similar to the current standard of care, Liposomal Amphotericin B, and when combined with LAMB, it resulted in a significant enhancement in survival and reduction in fungal burden in lung and brain tissue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
Rhea-AI Summary
SCYNEXIS, a biotechnology company (NASDAQ: SCYX), announced preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference. The study showed SCY-247's in vivo efficacy equivalent to currently used antifungals in treating a Mucorales pulmonary infection in immunosuppressed mice. The combination of SCY-247 with liposomal amphotericin B resulted in a significant survival improvement when compared to monotherapy. The study was funded by the National Institutes of Health (NIH) utilizing the National Institute of Allergy and Infectious Diseases suite of preclinical services for in vivo testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
conferences clinical trial
-
Rhea-AI Summary
SCYNEXIS, Inc. (NASDAQ: SCYX) reported financial results for Q3 2023, highlighting the progress of their next generation antifungal drug, SCY-247, and the evaluation of remediation strategies following the voluntary recall of BREXAFEMME® and the clinical hold on the MARIO trial. The company's cash position of $105.2 million provides a cash runway of over two years. SCYNEXIS also provided updates on the ibrexafungerp clinical and regulatory status, NMPA acceptance for review in China, and the preclinical development program for SCY-247. Financially, the company recognized a loss of ($0.6) million in product revenue and a net loss of $1.8 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
-
Rhea-AI Summary
SCYNEXIS presents preclinical data on second-generation antifungal candidate SCY-247 at medical mycology conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
clinical trial
Rhea-AI Summary
SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) due to potential cross contamination with a non-antibacterial ß-lactam drug substance, posing a risk of hypersensitivity reactions. No adverse events reported. The recalled lots were distributed nationwide. Consumers should contact their healthcare provider for any related issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
-
Rhea-AI Summary
SCYNEXIS, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
conferences
-
Rhea-AI Summary
SCYNEXIS reported closing of exclusive license agreement with GSK for BREXAFEMME. Received $90M upfront payment and $25M milestone payment. NDA for oral ibrexafungerp tablets accepted in China. Cash balance of $91.9M with projected cash runway beyond two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
earnings
Rhea-AI Summary
SCYNEXIS, Inc. announced that China’s NMPA has accepted for review a New Drug Application for oral ibrexafungerp tablets for the treatment of vulvovaginal candidiasis in China. The application is based on positive Phase 3 study results, and if approved, ibrexafungerp will be a new anti-fungal treatment for Chinese patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none
Scynexis Inc

Nasdaq:SCYX

SCYX Rankings

SCYX Stock Data

53.02M
36.73M
2.88%
49.08%
2.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Jersey City

About SCYX

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.